|
|
Vol. 26.02 – 10 February, 2025
|
|
|
|
|
|
|
|
Researchers found that viral evasins that partially reduced HLA class I expression could shelter CAR T cells from mismatched CD8+ T cells without triggering ‘missing-self’ rejection by NK cells. [Nature]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Investigators conducted a Phase I trial to test a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear cell renal cell carcinoma with or without ipilimumab administered adjacent to the vaccine.
[Nature]
|
|
|
|
|
|
To predict adeno-associated virus (AAV) capsid performance under near-clinical conditions, scientists established side-by-side comparison at single-cell resolution in human livers maintained by normothermic machine perfusion.
[Nature Biotechnology]
|
|
|
|
|
|
The authors leveraged prime editing of the high-copy-number, long interspersed nuclear element-1 retrotransposon to engineer incorporation of thousands of Cre-recombinase sites into the genomes of two human cell lines.
[Science]
|
|
|
|
|
|
In this first-in-human, Phase I, dose escalation, and expansion clinical trial, patients with relapsed or refractory large B-cell lymphoma received 19(T2)28z-1XX CAR T cells at four dose levels.
[Journal of Clinical Oncology]
|
|
|
|
|
|
Researchers presented a nanotechnology platform based on natural lipoproteins, designed for delivering small interfering RNA, antisense oligonucleotides, and messenger RNA to myeloid cells and hematopoietic stem and progenitor cells in the bone marrow.
[Nature Nanotechnology]
|
|
|
|
|
|
Using a genetically engineered mouse model of medulloblastoma, investigators showed that FLASH radiation stimulated proinflammatory polarization in tumor macrophages. [Nature Cancer]
|
|
|
|
|
|
Researchers used a mitochondrial DddA-derived cytosine base editor to correct a mutation in the mitochondrial DNA encoding a mitochondrial transfer RNA alanine.
[Science Translational Medicine]
|
|
|
|
|
|
A series of iteratively improved cytosine base editors were constructed using the FrCas9 nickase with the unique protospacer adjacent motif palindromic structure to alleviate these challenges.
[Nature Communications]
|
|
|
|
|
|
Researchers identified a therapeutic HLA-A*02-restricted protein tyrosine phosphatase receptor type Z1-reactive T cell receptor retrieved from a vaccinated glioblastoma patient.
[Nature Communications]
|
|
|
|
|
|
Scientists reported that TRIM21 impaired CD8+ T cell activation and anti-tumor immunity. Mechanistically, TRIM21 catalyzed the K63-linked ubiquitination on PD-1 at K233, leading to stabilization of PD-1 through antagonizing its K48-linked ubiquitination and degradation. [Molecular Therapy]
|
|
|
|
|
|
Researchers conducted a Phase I clinical trial of BMS-986354, an autologous BCMA CAR T manufactured using an optimized NEX-T® process, in participants with triple-class exposed, refractory multiple myeloma.
[Leukemia]
|
|
|
|
|
|
The authors demonstrated a gene editing approach that selectively targeted the dominant 3-base pair deletion in the TOR1A DYT1 allele while safeguarding the wild-type TOR1A allele.
[Molecular Therapy – Nucleic Acids]
|
|
|
|
|
|
|
|
Investigators summarize the current management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and review T cell- and myeloid cell-intrinsic druggable targets and cellular engineering strategies to develop safer CAR-T cells.
[Nature Reviews Drug Discovery]
|
|
|
|
|
|
Scientists provide background on the history and potential therapeutic value of mesenchymal stromal/stem cells (MSC), an overview of MSC products with regulatory approval, and a summary of registered MSC trials.
[Molecular Therapy]
|
|
|
|
|
|
The authors discuss the FDA’s approval of afami-cel, a first-in-class gene-modified autologous T cell therapy, for the treatment of specific solid tumor indications. [Cancer Letters]
|
|
|
|
|
|
|
|
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in most cancer types. The latest readout positions Breyanzi for a potential foray into marginal zone lymphoma, for which none of the existing CAR-T therapies are approved by the FDA. [Fierce Pharma]
|
|
|
|
|
|
|
|
March 18-19, 2025 London, England, United Kingdom
|
|
|
|
|
|
|
|
|
|
|
University of Wisconsin – Madison, Wisconsin, United States
|
|
|
|
|
|
|
Stanford – Palo Alto, California, United States
|
|
|
|
|
|
|
St. Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|
|
St. Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|
|
French National Institute for Health Research (INSERM) – Paris, France
|
|
|
|
|
|